Livzon Pharma announces further capital contribution to LivzonBio

Livzon Pharmaceutical Group Inc. (HKEX: 1513) has announced a connected transaction involving a capital contribution to LivzonBio, its biopharmaceutical platform subsidiary. The RMB1 billion capital injection aims to support LivzonBio's research and development, operations, and address its funding needs for loan repayments and future growth over the next two to three years. The valuation for this capital contribution is consistent with previous independent third-party investments, specifically referencing the Series A financing from 2018. This move is designed to reduce interest expenses and alleviate debt pressure on LivzonBio, which is focused on monoclonal antibodies, recombinant protein drugs, and innovative vaccines. The Directors consider the Capital Contribution is fair and reasonable.